Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

Cancer Research

Volumn 71, Issue 4, 2011, Pages 1362-1373

  Hu Lowe, Dana D ^a   Chen, Enhong ^a   Zhang, Lianglin ^a   Watson, Katherine D ^b   Mancuso, Patrizia ^d   Lappin, Patrick ^a   Wickman, Grant ^a,g   Chen, Jeffrey H ^a   Wang, Jianying ^a   Jiang, Xin ^a,h   Amundson, Karin ^a,i   Simon, Ronald ^e   Erbersdobler, Andreas ^f   Bergqvist, Simon ^a   Feng, Zheng ^a   Swanson, Terri A ^a   Simmons, Brett H ^a   Lippincott, John ^a,j   Casperson, Gerald F ^a   Levin, Wendy J ^a   Stampino, Corrado Gallo ^a   Shalinsky, David R ^a   Ferrara, Katherine W ^c   Fiedler, Walter ^e   Bertolini, Francesco ^d   more..

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^h Sova Pharmaceuticals   (United States)

ⁱ Tocagen Inc   (United States)

^j Igenica Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; DESMIN; MATRIGEL; PF 00337210; PF 03446962; PROTEIN TYROSINE KINASE INHIBITOR; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; CARCINOGENESIS; CELL DISRUPTION; CELL PROLIFERATION; CELL SPREADING; CELLULAR DISTRIBUTION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ECHOGRAPHY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LYMPHANGIOGENESIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR XENOGRAFT;

ACTIVIN RECEPTORS, TYPE II; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951828866     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1451     Document Type: Article

References (43)

1. Massagué J. TGFbeta in Cancer. Cell 2008;134:215-30.
2. Goumans MJ, Liu Z, ten-Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-27.
3. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000;26:328-31.
4. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626-31. (Pubitemid 30159221)
5. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptorlike kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003;93:682-9. (Pubitemid 37222165)
6. Niessen K, Zhang G, Ridgway JB, Chen H, Yan M. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood 2009;115:1654-61.
7. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis: tales of twosyndromes. Hum Mol Genet 2003;12:R97-112.
8. Sadick H, Riedel F, Naim R, Goessler U, Hörmann K, Hafner M, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-28.
9. Shi Y, Massagué J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 2003;113:685-700. (Pubitemid 36724933)
10. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijike P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21:1743-53.
11. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003;12:817-28. (Pubitemid 37352776)
12. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002;100:4495-501. (Pubitemid 35429690)
13. Mallet C, Vittet D, Feige JJ, Bailly S. TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells 2006;24:2420-7. (Pubitemid 44674302)
14. David L, Mallet C, Vailhe B, Lamouille S, Feige JJ, Bailly S. Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK. J Cell Physiol 2007;213:484-9. (Pubitemid 47509730)
15. Shao ES, Lin L, Yao Y, Boström KI. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009;114:2197-206.
16. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-72. (Pubitemid 46638511)
17. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85.
18. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-88.
19. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
20. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95. (Pubitemid 30208155)
21. Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R. Angiogenesis-regulating cytokines: activities and interactions. Curr Top Microbiol Immunol 1996;213:31-67.
22. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95. (Pubitemid 36554699)
23. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39. (Pubitemid 351413938)
24. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10. (Pubitemid 37328844)
25. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
26. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-4.
27. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-2. (Pubitemid 44283088)
28. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA. Suppression of spontaneous melanoma metastasis in SCID mice with an antibody to the epidermal growth factor receptor. Cancer Res 1991;51:2193-8.
29. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009;15:267-73.
30. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 2002;13:593-7. (Pubitemid 35448061)
31. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors inhuman skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-54. (Pubitemid 33049374)
32. Pollard RE, Sadlowski AR, Bloch SH, Murray L, Wisner ER, Griffey S, et al. Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat 2002;1:459-70. (Pubitemid 36548522)
33. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60. (Pubitemid 36749213)
34. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8. (Pubitemid 28256727)
35. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-49. (Pubitemid 47040874)
36. Wu J, Long Q, Xu S, Padhani AR. Study of tumor blood perfusion and its variation due to vascularnormalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech 2009;42:712-21.
37. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30. (Pubitemid 46836870)
38. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
39. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009;19:71-88.
40. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
41. Pollard RE, Dayton PA, Watson KD, Hu X, Guracar IM, Ferrara KW. Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model. Urology 2009;74:675-81.
42. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001;20:8334-41. (Pubitemid 34121904)
43. Mancuso P, Shalinsky DR, Calleri A, Quarma J, Antoniotti P, Jilani I, et al. Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF-03446962 undergoing phase I trial in cancer patients. J Clin Oncol 2009;27Suppl:164s. Abstract 3573.